Alantolactone is a sesquiterpene lactone compound derived primarily from the roots of Inula helenium (elecampane). Its use in supporting or treating skin infections is based primarily on emerging scientific evidence rather than a long-standing traditional application. Laboratory studies have shown that alantolactone exhibits antimicrobial and antifungal properties. For example, in vitro studies indicate alantolactone can inhibit the growth of several pathogenic bacteria and fungi, including Staphylococcus aureus and Candida albicans, both of which are relevant to skin infections.

Additionally, alantolactone has demonstrated anti-inflammatory and anti-biofilm activities. These mechanisms are of interest in the context of skin infections, where inflammation and biofilm formation can complicate healing and treatment. However, most evidence is preclinical: studies are limited to cell cultures and animal models. There is a lack of robust clinical trials evaluating the efficacy or safety of topical or systemic alantolactone in humans with skin infections. Thus, while the scientific rationale is promising and supported by initial laboratory data, clinical validation is currently insufficient.

In summary, the use of alantolactone for skin infections is justified by preliminary scientific evidence, but the overall quality and quantity of evidence is limited and does not yet support widespread clinical use.